<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557011</url>
  </required_header>
  <id_info>
    <org_study_id>NRP104.201</org_study_id>
    <nct_id>NCT00557011</nct_id>
  </id_info>
  <brief_title>NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled, 3-Treatment, 3-Period, Crossover Study With One Week Per Treatment and Once-a-Day Dosing of Either NRP104, Adderall XR, or Placebo in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New River Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New River Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess, in a controlled environment, the efficacy and safety
      of NRP104 and Adderall XR compared to placebo in treatment of children, aged 6-12, with ADHD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SKAMP-DS scores across a treatment assessment day</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SKAMP Attention Scale, PERMP attempted score, PERMP correct score, and CGI scores across the treatment assessment day</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile and PK/PD relationship of NRP104</measure>
    <time_frame>After multiple doses</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NRP104</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adderall XR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRP104</intervention_name>
    <description>30 mg, 50 mg or 70 mg capsules taken orally once daily in the morning</description>
    <arm_group_label>1</arm_group_label>
    <other_name>lisdexamfetamine dimesylate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adderall XR</intervention_name>
    <description>10 mg capsules taken once daily in the morning at dosages of either 1x10mg, 2x10mg or 3x10mg</description>
    <arm_group_label>2</arm_group_label>
    <other_name>mixed salts of a single-entity amphetamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule taken once daily in the morning</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males and non-pregnant females, aged 6-12 years DSM-IV-TR criteria for diagnosis of
             ADHD, combined or hyperactive-impulsive subtypes

          -  on stable regimen of stimulants for at least one month in the last six months and has
             shown adequate response to stimulants without unacceptable side effects

        Exclusion Criteria:

          -  co-morbid psychiatric diagnosis such as psychosis, bipolar illness, severe OCD, severe
             depressive or anxiety disorder

          -  history of seizure during the last 2 years, a tic disorder or Tourette's

          -  clinically significant ECG or laboratory abnormalities at screening or baseline

          -  taking clonidine or anticonvulsant drugs

          -  taking medications that affect blood pressure or heart rate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Biederman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samuel Boellner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Study Centers, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann Childress, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Psychiatry And Behavioral Medicine Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Lopez, M.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>FDA Recall information</description>
  </link>
  <results_reference>
    <citation>Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007 Nov 1;62(9):970-6. Epub 2007 Jul 12.</citation>
    <PMID>17631866</PMID>
  </results_reference>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2007</study_first_submitted>
  <study_first_submitted_qc>November 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2007</study_first_posted>
  <last_update_submitted>May 23, 2011</last_update_submitted>
  <last_update_submitted_qc>May 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2011</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
    <mesh_term>Adderall</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

